Lumpectomy to treat breast cancer has revolutionized the management of that disease.
Introduction
The use of breast sparing surgery ie "lumpectomy" to treat breast cancer has revolutionized the local control of that disease. Lumpectomy showed that the quality of life of the individual patient can successfully be integrated into the equation of cancer treatment without major loss of cancer treatment efficacy (1). Prostate cancer in men raises many of the same issues that breast cancer does in woman. Complications of prostate cancer treatment producing impotence and incontinence, effects the male self image and psyche no less than the loss of a breast does a woman. A number of recent studies have questioned the efficacy of an aggressive treatment approach to prostate cancer. Current management of prostate cancer covers both ends of the treatment spectrum. Patients can elect no treatment at all i.e., "watchful waiting" (2) or aggressive whole gland treatments such as radical prostatectomy, with no middle ground available. It stands to reason that if no treatment at all can be advocated for a subset of prostate cancer patients then the middle ground of attempting to just destroy the focus of cancer in the gland could be a viable option. In this article we will discuss the rationale for the "Male Lumpectomy" approach for prostate cancer and the early results we previously reported in the literature.
re-biopsy of the patient with an optimized biopsy protocol in the area of previously negative biopsy. The biopsies were carried out with 5 cores taken from the lateral peripheral zone and 3 cores from the medial transition zone. Subsequent biopsies in the last year were carried out using a new 3D global mapping method using a brachytherapy grid. Biopsies in this method are taken every 5 millimeters through the length of the prostate. These biopsies were carried out under sedation anesthesia.
The ultrasound guided percutaneous prostate cryosurgery procedure was carried out as described originally by Onik et al. (3) . The extent of freezing was tailored to the particular patient and was determined by the patient's clinical parameters, which included; tumor location, Gleason grade, stage, and PSA level. The only criteria for inclusion was the extent of the patients disease. No patient was excluded because of Gleason grade or PSA level. Patients with increased risks factors however were encouraged to go on CHT for 3 to 6 months prior to the cryosurgery. To prevent local recurrence, the neurovascular bundle was destroyed on the side of the patient's tumor. An attempt was made to spare one neuro-vascular bundle on the side opposite the tumor. Improvements over the original Onik et al. procedure included monitoring of temperatures in critical locations and the separation of the rectum and the prostate by a saline injection at the time of the procedure, to prevent rectal injury and to allow adequate peri-prostatic freezing.
Post operatively, all patients were removed from combined hormonal therapy immediately after the procedure. A PSA was obtained every 3 months for the first two years and then every 6 months thereafter. Patients were considered to have a stable PSA if they had two consecutive PSA's without a rise. Patients were followed up by written questionnaire and phone call. Patients were considered potent if they had erections sufficient for vaginal penetration and they were satisfied with their sexual functioning.
Results
The results on this focal nerve sparing approach to cryoablation we recently reported in the journal Urology (4) are very encouraging. The results showed that between 6/95 and 11/00, 9 patients could be evaluated who had focal, nerve sparing cryosurgery (Table I) . Follow up ranged from 6-72 months with a mean of 36 months. Three of the patients has bilateral gland freezing with attempt to only spare the neurovascular bundle. One patient had only the area of the tumor, with an appropriate margin around the tumor, frozen. The remainder of the patients had half of the gland frozen. All the patients had stable PSA's; with the post-op PSA stabilizing at some fraction of the pre-op PSA, depending on the extent of the gland freeze. Six patients, who were biopsied routinely, had negative biopsies. The mean and median preoperative PSA's were 8.02 ng/ml and 7.01 ng/ml (SD+-4.4) respectively. The mean and median postoperative PSA's were 1.47 ng/ml and .72 ng/ml (SD +-1.57) respectively. Biopsies of the treated areas in all patients showed coagulative necrosis, benign stroma and inflammatory infiltrates. Biopsies in untreated areas showed benign normal prostate in all patients except one (patient 6 in table, in which one core showed low grade PIN). Subsequent biopsy a year later in this patient was negative. No patient required additional treatment, Potency was been maintained in 7 of 9 patients. No instances of other complications previously described with cryosurgery such as obstruction, incontinence, penile numbness or fistula formation occurred. Since that publication an additional 9 patients have reached the 2 yr follow up mark. Data on these additional patients is currently being analysed. It is known however that one patient has had a positive biopsy in a previously spared region and now has a negligible PSA after having that region treated.
Results on the new method of 3D global mapping biopsy using the brachytherapy grid have been very interesting. Twenty-five patients have now had biopsies carried out in this manner. The number of cores taken ranged from 17-65 (mean=40). 15 of 25 patients had cancer demonstrated in the previously negative lobe. 3 of these 15 patients upgraded their Gleason score. One patient had hematuria requiring catheter drainage (3 days). No other complications were noted.
Case Study
A 67 yr. old electrical engineer was diagnosed with adenocarcinoma of the prostate. At the time of his diagnosis his PSA was 1.5 and his rectal exam was positive on the left side of his gland prompting a biopsy. The ultrasound guided biopsy showed a Gleason 7 adenocarcinoma in one core from the left base of his gland. He presented to us as a self referral for prostate cryosurgery. He was very concerned about maintaining potency and limiting chances for complications and was offered a hemi-cryoprostatectomy as an alternative treatment. The patient had the right side of his prostate re-biopsied with 9 cores taken, 5 from the lateral peripheral zone, 3 from the medial gland and 1 through the ejaculatory duct region. These biopsies showed no evidence for cancer on the side opposite his tumor and he was therefore felt to be a good candidate for the procedure. Despite our urging the patient refused to be placed on preoperative combined hormonal therapy and immediately underwent a left hemi-cryoprostatectomy. The procedure was carried out uneventfully and the patient had the Foley catheter removed at 10 days. His PSA fell to .5 ng/ml by 3 months post operatively and has remained at that level now 2 years post treatment. Post cryosurgery biopsies under ultrasound guidance 1 and 2 years out were done. Pathology from the left (treated side) showed stromal elements without glands present. The untreated side (right side) showed low grade PIN on the first biopsy and normal prostate tissue on the 2 nd biopsy. Ultrasound of the prostate showed marked atrophy of the left side of the gland. The patient had return of his potency 6 months after the procedure.
Discussion
When advocating the approach of "cryolumpectomy" for prostate cancer, three main questions must be considered.
Does the pathologic literature support a focal approach to treating prostate cancer?
The main theoretical objection to a lumpectomy type approach to prostate cancer is the realization that prostate cancer is often a multi-focal disease within the prostate. As in breast cancer however prostate cancer is a spectrum of diseases some of which are may be amenable to lumpectomy and others that may not. The pathological literature clearly shows that many patients do not have multi-focal prostate cancer. Until now however, little attention has been paid in trying to differentiate those patients with uni-focal (a single focus of cancer), from multi-focal disease (multiple independent cancers irrespective of their size). The reason being that it had little clinical significance with treatments aimed at total gland removal or destruction. In a study examining radical prostatectomy specimens Djavan et al. (5) showed that patients with unifocal disease constituted one third of the cases studied and could be reliably differentiated from patients with uni-focal disease with a sensitivity of 90% using the PSA density of the transition zone and percent free to total PSA. In addition, Villiers et al. (6), however, showed that 80% of multi-focal tumors are less than .5 cc's indicating they may not be of clinical significance. This study was confirmed by Rukstalis et al. (7) in which pathologic examination showed that based on the un-ifocality and size criteria of 5 mm or less, 80% of patients might be a candidate for a focal treatment approach. Clearly then based on the known pathology of prostate cancer an opportunity exists to investigate a focal treatment.
It has been demonstrated, as well, that optimization of biopsy results by a second set of biopsies and improved gland sampling can greatly diminish the chances of missing a significant multi-focal tumor (8). In addition, demonstration of negative biopsies on the nerve sparing side is an excellent predictor of negative margins at nerve sparing RP (9). One of the strengths of the procedure that we describe is the ability to tailor the procedure, based on the threat of disease in the opposite prostate lobe. Three of our patients at high risk for multi-focal disease, had bilateral prostate freezing, with only NVB sparing on the side opposite the cancer. On the other hand, our most recently treated patient had a well-defined (on both MRI and US) 6-mm tumor of Gleason grade 3. Biopsies surrounding the visible abnormality showed no cancer therefore, a minimal, focal procedure, only directed to the visible tumor and a surrounding margin of tissue and NVB, was carried out. The reward for this minimal treatment was that the patient did not need a Foley catheter post operatively and was sexually active one week after the procedure.
Saturation biopsy techniques (not carried out in our original series) now being used, in which the gland is biopsied every 5 mm's using a brachytherapy type grid could also have an impact on excluding patients with significant multi focal disease. Results in 25 patients undergoing 3D global mapping biopsies showed that cancer could be demonstrated in 50% of patients who previously had negative biopsies in the supposedly uninvolved prostate lobe. Lastly, if a mistake in patient selection were made, a level of comfort with a focal cryosurgery is possible, since unlike nerve sparing RP and brachytherapy, cryosurgery has the unique ability to allow repeat cryosurgical treatments without added morbidity.
Is whole gland cryoablation a safe and effective treatment for prostate cancer?
Since the anatomy of the prostate gland does not make it amenable to partial removal or lumpectomy, tumor destruction by another is needed to realize a lumpectomy in a male. Cryoablation has a long history of effective tumor treatment and has been shown to be an effective and safe alternative in treating the whole gland with prostate cancer. Approximately 3 years ago prostate cryoablation was approved by Medicare as a treatment for primary prostate cancer (removing from the investigational category) and the only treatment specifically approved for treating patients with recurrent cancer after radiation therapy. Long term 5 and 7 year data recently published by Donnelly et al. (10) and Bahn et al. (11) is now available that confirms cryoablation as a treatment competitive to both surgery and radiation in treating prostate cancer. A recently published article by Katz (12) reviewed the 5 year biochemical disease free survival of patients treated with brachytherapy, CT conformal radiation therapy, radical prostatectomy and cryoabaltion for every article published in the last 10 years. The results were stratified based on whether the patients were low, medium or high risk for biochemical failure. Based on this analysis the range of results for cryosurgery was equivalent to all other treatments in low and medium risk patients and appeared to be superior in high risk patients. Overall complications rates were similar with all the modalities. The only article directly comparing cryosurgery with radical prostatectomy published by Gould et al. (13) showed cryosurgery to be equivalent to RP in low risk patients but as patient's preoperative PSA increased, cryosurgery results were superior to RP. The basis for this apparent superiority in high risk patients may be the ability for cryoablation to be repeated if needed. Based on these results one could conclude that cryoablation is a safe and effective treatment for treating prostate cancer and it's inherent ability to be tailored to the extent of the patients disease makes it a platform upon which a treatment such as a lumpectomy can be based.
Do the initial results of "male lumpectomy" for prostate cancer indicate that such an approach can control cancer and limit the complications such as impotence and incontinence traditional associated with prostate cancer?
The results recently reported in the journal Urology for focal cryosurgery (4) are very encouraging. The mean follow-up of the 9 patients reported was 3 years. Potency was maintained in 7 of the 9 patients (78%) with no patient demonstrating incontinence. Based on re-biopsy post treatment and stability of PSA all patients were free of disease. This was of greater significance because 5 of the 9 patients were in a medium to high risk category and were not narrowly selected for favorable clinical parameters as were patients in the early brachytherapy series. Initial results on an additional 10 patients treated since publication of this article have so far confirmed these results.
The procedure we describe of focal "nerve sparing" prostate cryosurgery is an attempt to combine the advantages of cryosurgery, that of excellent treatment of extra-capsular extension and low general morbidity, while preserving the patient's potency. The procedure we performed is a unique combination of an aggressive treatment on the side of the cancer (freezing was extended beyond the capsule and included the confluence of the seminal vesicles and the NVB on the side of the tumor) yet a "minimal" procedure on the side opposite the cancer.
Within the context, of our mean follow up of 36 months, this approach has been successful in local cancer control, with no evidence for local recurrence in an area frozen in any of the patients to date.
One of the difficulties of our treatment approach is defining a successful result, from the cancer recurrence point of view. In this procedure variable amounts of prostatic tissue on the side opposite the tumor are knowingly left untreated. Depending on the degree of tissue untreated we expect to see a post operative, PSA reading above .2 ng/ml. As in patients without prostate cancer, however, we would expect PSA stability, i.e., no rise in PSA over time in patients adequately treated. This criteria of PSA stability coupled with negative biopsy results is consistent with common sense clinical practice and resulted in none of the patients reported needing further work up or treatment for a cancer recurrence.
The procedure appears to have extremely low morbidity. No significant blood loss or peri-operative cardiac or pulmonary complications occurred, nor were they expected, since even with total gland ablation these are ussually not a problem. In total gland cryosurgical ablation, incontinence is seen in less than 2% of patients (14) . Incontinence, with our more minimal cryosurgical approach, would be expected to be negligible, where a nerve sparing radical prostatectomy, may have incontinence rates as high as 6% (15).
The preservation of potency associated with the "male lumpectomy" is better than we expected with 80% of patients satisfied with their sexual functioning. In our approach only one neuro-vascular bundle is spared making these results somewhat surprising. The literature on nerve sparing RP shows a significantly low potency rate of around 30% vs 50% when one NVB is spared vs. two, respectively (15, 16). In essence we were able to achieve a higher potency rate with our unilateral nerve sparing procedure then one would expect for a bilateral nerve sparing RP, without risking a positive margin on the tumor side as can occur with RP. These superior results for cryosurgery in unilateral nerve sparing may be explained by cryosurgery's minimal vascular disruption and the lack of nerve manipulation and trauma, when compared to radical prostatectomy.
Another difference in our results, when compared to RP nerve sparing, appears to be in the rate of potency return between the two procedures. Potency rates in RP nerve sparing procedures are often reported after 18 months post RP. In our experience the return to function after focal cryosurgery is very rapid. All patients have had return to sexual functioning within 1 year of the procedure. The rapidity of return seemed in part, related to whether the patient had been on pre-operative hormone therapy, as well as the extent of freezing that was carried out.
Cryolumpectomy seems to have advantages over brachytherapy and external beam radiotherapy, as well. Unlike brachytherapy, which is limited to patients with low volume, low Gleason grade disease; our procedure is limited by whether the disease is confined to one side of the gland, rather than these other clinical parameters. Based on Gleason grade, PSA levels and extent of disease, more than half of the patients we treated would not have been candidates for brachytherapy alone.
Radiation therapy does not appear to maintain it's initial potency sparing advantage over the long term. Potency rates after 2 years are essentially equivalent with nerve sparing radical prostatectomy (17). Brachytherapy's urinary tract complications can have a significant effect on patient lifestyle and rectal complications, a major concern with radiation therapy, have been virtually eliminated in our procedure, by separation of the rectum and prostate with saline injection into Denonvillier's Fascia prior to freezing (protection of the bladder and ureters has not been shown to be needed when performing cryosurgery). In addition, brachytherapy patients who fail locally have limited curative options available. Lastly, a major drawback to radiation therapy is that patients who fail radiation show a significant increase in Gleason grade and tumor aggressiveness in the recurrent cancer adversely effect patient survival (18). Certainly this is not a favorable characteristic in a procedure being applied to possibly a younger patient population in order to save potency.
In conclusion, preliminary results have shown that a procedure which effectively targets the cancerous portion of the prostate gland (i.e., a "male lumpectomy") while limiting patient morbidity, is possible. In this time when patients must choose between "watchful waiting" or high morbidity whole gland treatments, such a focal approach to prostate cancer treatment would be a welcome addition to the treatment armamentarium.
